Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 15.95% and Operating profit at 14.38% over the last 5 years
2
Negative results in Sep 25
3
With ROE of 20.16%, it has a expensive valuation with a 6.46 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 36,352 Million (Large Cap)
32.00
NA
2.81%
-0.26
18.56%
4.16
Revenue and Profits:
Net Sales:
1,129 Million
(Quarterly Results - Mar 2026)
Net Profit:
442 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.22%
0%
-10.22%
6 Months
-20.15%
0%
-20.15%
1 Year
-7.92%
0%
-7.92%
2 Years
-33.05%
0%
-33.05%
3 Years
-8.49%
0%
-8.49%
4 Years
20.82%
0%
20.82%
5 Years
-64.42%
0%
-64.42%
Shenzhen New Industries Biomedical Engineering Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.95%
EBIT Growth (5y)
14.38%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.53
Tax Ratio
12.50%
Dividend Payout Ratio
55.86%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
40.76%
ROE (avg)
19.99%
Valuation key factors
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
6.46
EV to EBIT
29.85
EV to EBITDA
26.35
EV to Capital Employed
7.95
EV to Sales
11.51
PEG Ratio
NA
Dividend Yield
1.90%
ROCE (Latest)
26.62%
ROE (Latest)
20.16%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,128.60
1,149.10
-1.78%
Operating Profit (PBDIT) excl Other Income
514.10
556.10
-7.55%
Interest
0.10
0.10
Exceptional Items
4.10
0.00
Consolidate Net Profit
442.00
415.40
6.40%
Operating Profit Margin (Excl OI)
455.50%
432.90%
2.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -1.78% vs -7.54% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 6.40% vs -4.22% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,532.90
4,529.40
0.08%
Operating Profit (PBDIT) excl Other Income
1,991.20
2,151.70
-7.46%
Interest
2.80
2.50
12.00%
Exceptional Items
17.30
27.70
-37.55%
Consolidate Net Profit
1,620.30
1,828.50
-11.39%
Operating Profit Margin (Excl OI)
387.50%
426.70%
-3.92%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.08% vs 15.46% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -11.39% vs 10.57% in Dec 2024
About Shenzhen New Industries Biomedical Engineering Co., Ltd. 
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






